Identification of a bilirubin receptor that may mediate a component of cholestatic itch

Abstract

Various pathologic conditions result in jaundice, a yellowing of the skin due to a buildup of bilirubin. Patients with jaundice commonly report experiencing an intense non-histaminergic itch. Despite this association, the pruritogenic capacity of bilirubin itself has not been explored, and no bilirubin receptor has been identified. Here, we demonstrate that pathophysiologic levels of bilirubin excite peripheral itch sensory neurons and elicit pruritus through MRGPRs, a family of G-protein coupled receptors expressed in primary sensory neurons. Bilirubin binds and activates two MRGPRs, mouse MRGPRA1 and human MRGPRX4. In two mouse models of pathologic hyperbilirubinemia, we show that genetic deletion of either Mrgpra1 or Blvra, the gene that encodes the bilirubin-producing enzyme, attenuates itch. Similarly, plasma isolated from hyperbilirubinemic patients evoked itch in wild-type animals but not Mrgpra1-/- animals. Removing bilirubin decreased the pruritogenic capacity of patient plasma. Based on these data, targeting MRGPRs is a promising strategy for alleviating jaundice-associated itch.

Data availability

All data generated or analyzed during this study are included in the manuscript. Source data for main figures 1-7 have been provided.

Article and author information

Author details

  1. James Meixiong

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    James Meixiong, is a consultant for Escient Pharmaceuticals a company focused on developing small molecule inhibitors for MRGPRs.
  2. Chirag Vasavda

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  3. Dustin Green

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Qin Zheng

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  5. Lijun Qi

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  6. Shawn G Kwatra

    Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. James P Hamilton

    Department of Medicine, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  8. Solomon H Snyder

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    For correspondence
    ssnyder1@jhmi.edu
    Competing interests
    No competing interests declared.
  9. Xinzhong Dong

    Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, United States
    For correspondence
    xdong2@jhmi.edu
    Competing interests
    Xinzhong Dong, has a financial interest in Escient Pharmaceuticals a company focused on developing small molecule inhibitors for MRGPRs.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9750-7718

Funding

National Institute of Neurological Disorders and Stroke (R01NS054791)

  • Xinzhong Dong

Howard Hughes Medical Institute

  • Xinzhong Dong

National Institute of Mental Health (MH18501)

  • Solomon H Snyder

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were performed in accordance with protocols approved by the Animal Care and Use Committee at the Johns Hopkins University School of Medicine. All animals were handled according to approved institutional animal care and use committee (IACUC) protocols (MO16M40) of Johns Hopkins University.

Copyright

© 2019, Meixiong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 15,747
    views
  • 890
    downloads
  • 89
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. James Meixiong
  2. Chirag Vasavda
  3. Dustin Green
  4. Qin Zheng
  5. Lijun Qi
  6. Shawn G Kwatra
  7. James P Hamilton
  8. Solomon H Snyder
  9. Xinzhong Dong
(2019)
Identification of a bilirubin receptor that may mediate a component of cholestatic itch
eLife 8:e44116.
https://doi.org/10.7554/eLife.44116

Share this article

https://doi.org/10.7554/eLife.44116

Further reading

    1. Neuroscience
    Ana Maria Ichim, Harald Barzan ... Raul Cristian Muresan
    Review Article

    Gamma oscillations in brain activity (30–150 Hz) have been studied for over 80 years. Although in the past three decades significant progress has been made to try to understand their functional role, a definitive answer regarding their causal implication in perception, cognition, and behavior still lies ahead of us. Here, we first review the basic neural mechanisms that give rise to gamma oscillations and then focus on two main pillars of exploration. The first pillar examines the major theories regarding their functional role in information processing in the brain, also highlighting critical viewpoints. The second pillar reviews a novel research direction that proposes a therapeutic role for gamma oscillations, namely the gamma entrainment using sensory stimulation (GENUS). We extensively discuss both the positive findings and the issues regarding reproducibility of GENUS. Going beyond the functional and therapeutic role of gamma, we propose a third pillar of exploration, where gamma, generated endogenously by cortical circuits, is essential for maintenance of healthy circuit function. We propose that four classes of interneurons, namely those expressing parvalbumin (PV), vasointestinal peptide (VIP), somatostatin (SST), and nitric oxide synthase (NOS) take advantage of endogenous gamma to perform active vasomotor control that maintains homeostasis in the neuronal tissue. According to this hypothesis, which we call GAMER (GAmma MEdiated ciRcuit maintenance), gamma oscillations act as a ‘servicing’ rhythm that enables efficient translation of neural activity into vascular responses that are essential for optimal neurometabolic processes. GAMER is an extension of GENUS, where endogenous rather than entrained gamma plays a fundamental role. Finally, we propose several critical experiments to test the GAMER hypothesis.

    1. Medicine
    2. Neuroscience
    LeYuan Gu, WeiHui Shao ... HongHai Zhang
    Research Article

    The advent of midazolam holds profound implications for modern clinical practice. The hypnotic and sedative effects of midazolam afford it broad clinical applicability. However, the specific mechanisms underlying the modulation of altered consciousness by midazolam remain elusive. Herein, using pharmacology, optogenetics, chemogenetics, fiber photometry, and gene knockdown, this in vivo research revealed the role of locus coeruleus (LC)-ventrolateral preoptic nucleus noradrenergic neural circuit in regulating midazolam-induced altered consciousness. This effect was mediated by α1 adrenergic receptors. Moreover, gamma-aminobutyric acid receptor type A (GABAA-R) represents a mechanistically crucial binding site in the LC for midazolam. These findings will provide novel insights into the neural circuit mechanisms underlying the recovery of consciousness after midazolam administration and will help guide the timing of clinical dosing and propose effective intervention targets for timely recovery from midazolam-induced loss of consciousness.